Intra-Cellular Therapies Inc. (NASDAQ:ITCI) SVP Kimberly E. Vanover sold 1,185 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $17.37, for a total transaction of $20,583.45. Following the transaction, the senior vice president now directly owns 26,803 shares of the company’s stock, valued at $465,568.11. The sale was disclosed in a document filed with the SEC, which is available through this link.

Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded up $0.13 during mid-day trading on Friday, reaching $17.47. 989,961 shares of the company’s stock traded hands, compared to its average volume of 443,629. The stock has a market cap of $953.47, a PE ratio of -7.98 and a beta of 0.72. Intra-Cellular Therapies Inc. has a 12-month low of $7.85 and a 12-month high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. Intra-Cellular Therapies’s revenue for the quarter was up 675.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.70) EPS. analysts predict that Intra-Cellular Therapies Inc. will post -2.13 EPS for the current year.

ITCI has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research note on Wednesday, November 8th. BTIG Research reissued a “buy” rating and set a $36.00 price objective on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. Piper Jaffray Companies raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $14.00 to $33.00 in a research note on Thursday, September 7th. SunTrust Banks reissued a “hold” rating and set a $22.00 price objective (up from $16.00) on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. Finally, ValuEngine cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $25.56.

A number of hedge funds have recently added to or reduced their stakes in the business. BB Biotech AG grew its stake in Intra-Cellular Therapies by 11.7% in the 2nd quarter. BB Biotech AG now owns 2,150,000 shares of the biopharmaceutical company’s stock worth $26,703,000 after acquiring an additional 225,000 shares during the period. Wasatch Advisors Inc. grew its stake in Intra-Cellular Therapies by 18.7% in the 3rd quarter. Wasatch Advisors Inc. now owns 1,970,181 shares of the biopharmaceutical company’s stock worth $31,089,000 after acquiring an additional 310,668 shares during the period. State Street Corp grew its stake in Intra-Cellular Therapies by 10.4% in the 2nd quarter. State Street Corp now owns 1,004,360 shares of the biopharmaceutical company’s stock worth $12,474,000 after acquiring an additional 94,763 shares during the period. Dimensional Fund Advisors LP grew its stake in Intra-Cellular Therapies by 45.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 938,980 shares of the biopharmaceutical company’s stock worth $14,817,000 after acquiring an additional 291,793 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at $14,667,000. 74.47% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2018/01/05/kimberly-e-vanover-sells-1185-shares-of-intra-cellular-therapies-inc-itci-stock.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.